首页> Current medical research and opinion> New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials

New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials

导出原文传递

翻译打印收藏纠错

第一作者： Gottwald-Hostalek, Ulrike

作者： Gottwald-Hostalek, Ulrike ^[1] ; Uhl, Wolfgang ^[2] ; Wolna, Peter ; Kahaly, George J.

作者单位： Merck KGaA, Frankfurterstr 250, D-64293 Darmstadt, Germany ^[1] Johannes Gutenberg Univ Mainz, Med Ctr, Mainz, Germany ^[2]

关键词 Bioequivalence dosage form proportionality levothyroxine pharmacokinetic trials specification

发布时间 2018-11-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览2

Current medical research and opinion

2017年33卷2期

169-174页

相似文献

中文期刊
外文期刊
学位论文
会议论文

浏览2

点击下载本期目录封面

Current medical research and opinion

2017年33卷2期

169-174页

检索历史清除

New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials

Current medical research and opinion

相似文献

同项目论文

Current medical research and opinion

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

New levothyroxine formulation meeting 95-105% specification over the whole shelf-life: results from two pharmacokinetic trials

Current medical research and opinion

相似文献

同项目论文

Current medical research and opinion

相关期刊

检索历史清除